Gottlieb Sees Opportunity For Pharma To Seek Continuity Of COVID-19 Trial Accommodations
Executive Summary
Decentralized and remote flexibilities should stay, Gottlieb says, but so should e-detailing efforts.
You may also be interested in...
Pandemic Clinical Trials Need More Top-Down Control, Gottlieb Says
Ex-FDA commissioner offers British platform trials as examples of research done right, as he worries about studies that aren’t going to yield ‘definitive information’ crowding out trials that are more compelling and for more promising COVID-19 therapeutics.
Bayer Execs On Digital Acceleration, Getting The Building Blocks Right
Senior executives from Bayer outlined at a recent summit the contours of digital transformation already underway and the vital components of a successful digital team. Firms need to be able to operate technology at the “speed of business” and not “at the speed of a ticketing queue.”
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.